Innate Pharma Releases Its 2026 Financial Calendar Innate Pharma (Nasdaq: IPHA / Euronext: IPH) published its 2026 financial calendar with key publication and corporate dates. All scheduled reports will be released before market opens CET and corporate information will be available in the investors section of the company website.26 Mar 2026 – Publication of 2025 financial statements13 May 2026 – Publication of revenue and cash position for 1Q202621 May 2026 – Annual General Shareholders Meeting17 Sep 2026 – Publication of half year financial statements05 Nov 2026 – Publication of revenue and cash position for 3Q2026

#IPHA Innate Pharma Releases Its 2026 Financial Calendar

www.stocktitan.net/news/IPHA/innate-pharma-...

The Passive House Institute was represented by Dragoș Arnăutu at the nZEB Expo in Cluj-Napoca, on October 24-26, 2025 handing over of eight Passive House building certifications. Congrats to all construction teams and building owners!

#iPHA #iPHAAffiliate #PassiveHouseInstitute #PassivhausInstitut

Passivhaus on Tour in #Baesweiler, Part II:
The new BürgerMitteBaesweiler now serves as the administrative center. The old town hall was completely gutted and renovated using Passivhaus components.

🔗 https://ow.ly/Vnwv50Xqu86

#iPHA #iPHAAffiliate #PassiveHouseInstitute #PassivhausInstitut

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results Innate Pharma (NASDAQ:IPHA) reported Q3 2025 business and financial results on November 13, 2025. Key clinical milestones: FDA cleared the confirmatory Phase 3 protocol for lacutamab (TELLOMAK-3) enabling H1 2026 initiation and a potential accelerated approval path in Sézary syndrome; IPH4502 Phase 1 reached a pharmacologically active dose with enrollment continuing; monalizumab PACIFIC-9 data expected H2 2026. Financials: cash, equivalents and financial assets of €56.4 million as of Sept 30, 2025, with anticipated cash runway to end Q3-2026. Company reiterated ATM program of up to $75M and announced a planned redundancy plan to streamline operations.

#IPHA Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL Innate Pharma SA today announced that the U.S. Food and Drug Administration has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas, with no further comments, clearing the trial to proceed. The planned confirmatory Phase 3 trial, TELLOMAK 3, is an open-label, randomized study designed to demonstrate the...

#IPHA Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates Innate Pharma (Nasdaq: IPHA) will host a conference call and webcast on Thursday, November 13, 2025 at 2:00 p.m. CET / 8:00 a.m. ET to review business progress for the third quarter of 2025.Presenters include Jonathan Dickinson (CEO), Sonia Quaratino (EVP, CMO), Yannis Morel (EVP, COO), Stéphanie Cornen (VP, Investor Relations) and Frédéric Lombard (SVP, CFO). The live webcast is available at the event link and a replay will be posted on the company website for 90 days after the event.

#IPHA Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

www.stocktitan.net/news/IPHA/innate-pharma-...

🌿🏙️ @PHCA at Greenbuild 2025!
Nov 4–7 in LA, the Greenbuild Expo brings 10,000+ professionals together to explore sustainability, resilience & wellness. Catch @PHCA at Booth 815 on Nov 5–6 to see the latest Passive House innovations!
🔗 https://passivehousecal.org

#iPHA #iPHAAffiliate #Passivhaus

👮‍♀️ The UK’s first Passivhaus Police Station is here!
A groundbreaking moment for energy-efficient public buildings — designed to protect both people and the planet. 🌍💙
Read more 👉 www.passivhaustrust.org.uk/news/detail/

#iPHA #PassiveHouseInstitute #PassivhausInstitut #Passivhaus

🍏🏡 #PassiveHouse meets cider!
Join Plataforma PEP's 17th Spanish Passivhaus Conference in Avilés, Asturias — learn about sustainable design while discovering how Asturian cider is made.
A perfect blend of knowledge, culture & flavour! 🇪🇸✨
👉 https://conferencia-pep.org/

#iPHA

Innate Pharma Reports First Half 2025 Business Update and Financial Results Innate Pharma (NASDAQ:IPHA) reported its H1 2025 business update and financial results, highlighting significant progress in its clinical pipeline. The company announced a strategic restructuring, including a 30% workforce reduction and prioritization of key clinical assets: IPH4502, lacutamab, and monalizumab.Key developments include FDA Breakthrough Therapy Designation for lacutamab in February 2025, progression of IPH4502 Nectin-4 ADC Phase 1 enrollment, and completion of AstraZeneca's Phase 3 PACIFIC-9 enrollment for monalizumab. The company secured a €15 million equity investment from Sanofi in April 2025.Financial position shows cash of €70.4 million as of June 30, 2025, with runway until Q3-2026. Revenue decreased to €4.9 million in H1 2025 from €12.3 million in H1 2024. Management changes include Eric Vivier's departure as CSO and Yannis Morel assuming CSO responsibilities.

#IPHA Innate Pharma Reports First Half 2025 Business Update and Financial Results

www.stocktitan.net/news/IPHA/innate-pharma-...

French Biotech Innate Pharma Joins Elite European Midcap Event for Strategic Investor Meetings in Paris Innate Pharma's CFO Frédéric Lombard will participate in the 25th European Midcap Event in Paris, Sept 30-Oct 1, 2025, connecting with institutional investors for strategic discussions.

#IPHA Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

www.stocktitan.net/news/IPHA/innate-pharma-...

Earnings This Week :

#CODA #HAIN #HYFT #PLAY #CSBR #HITI #FERG #EPM #FLUX #GIS #HTOO #IPHA #MANU #QSG #CBRL #NNDM #SANG #DRI #FDS #FDX #LEN #RSSS #SCHL #BTC

Biotech Leader Innate Pharma Sets Key H1 2025 Financial Results and Pipeline Update Conference French biotech Innate Pharma (IPHA) to present H1 2025 financial results and business update on Sept 17, 2:00 PM CEST. Key executives including CEO and CMO to discuss company progress.

#IPHA Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

www.stocktitan.net/news/IPHA/innate-pharma-...

Hohe #Energieeffizienz und Denkmal:
"Hotel Marcel" des #Bauhaus Designers Marcel #Breuer nun klimafreundlich und mit tollem Raumkomfort.
Webinar "Spotlight" des Netzwerks #ipha stellt die beeindruckende Verwandlung des #Brutalismus Gebäudes vor: Mittwoch, 3. September.
ow.ly/2SMk50WMIOI

Innate Pharma CEO to Lead Fireside Chat at BTIG Conference as Analyst Coverage Begins CEO Jonathan Dickinson leads fireside chat on July 30 at newly covered BTIG Biotech Conference. 1-on-1 investor meetings available. Get details.

#IPHA Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Doubles Down on Investor Outreach: Set for HC Wainwright and Wolfe Research Healthcare Forums Innate Pharma executives to showcase at H.C. Wainwright Immune Cell Engager and Wolfe Research Biotech conferences. Get exclusive insights.

#IPHA Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides Innate Pharma (IPHA) has announced compelling long-term follow-up data from the Phase 2 TELLOMAK trial evaluating lacutamab in treating Sézary syndrome (SS) and mycosis fungoides (MF). The trial demonstrated significant results with a 42.9% overall response rate in SS patients and an impressive median duration of response of 25.6 months. For MF patients, the study showed a 19.6% overall response rate with a median duration of response of 13.8 months. Notably, lacutamab was recently granted Breakthrough Therapy Designation by the FDA for Sézary syndrome treatment. The drug showed strong tolerability and effectiveness in heavily pretreated patients, with anti-tumor activity observed across all patients regardless of KIR3DL2 expression levels. The company is now preparing for a Phase 3 trial to advance this promising therapy.

#IPHA Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Transforms Leadership: New Board Structure Brings International Standards, Staatz-Granzer Named Chair Strategic governance shift brings new CEO Jonathan Dickinson and Chairman Irina Staatz-Granzer. See how this transformation aligns with global standards. Learn more.

#IPHA Outcome of Innate Pharma’s 2025 Annual General Meeting

www.stocktitan.net/news/IPHA/outcome-of-inn...

ASCO 2025: Innate Pharma Reveals Long-Term Results for Rare Blood Cancer Treatment TELLOMAK Plus 3 More Studies Latest clinical data from TELLOMAK Phase 2 trial in rare lymphomas, plus updates on solid tumor ADC and AstraZeneca NSCLC collaboration. See full results.

#IPHA Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress Innate Pharma (NASDAQ: IPHA) announced the selection of abstracts for presentation at the European Hematology Association (EHA) Congress 2025 in Milan, Italy. The first abstract features IPH6501, their ANKET® therapy targeting CD20 B cells for relapsed/refractory Non-Hodgkin Lymphoma, which will be presented in a poster session on June 14, 2025. Additionally, an abstract about SAR'514/IPH6401, developed in partnership with Sanofi for Multiple Myeloma treatment, was accepted for online publication.

#IPHA Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results Innate Pharma (IPHA) reported Q1 2025 business update with significant pipeline developments. Key highlights include a €15 million investment from Sanofi and pipeline progress across multiple programs. The company achieved a major milestone with FDA Breakthrough Therapy Designation for lacutamab in treating relapsed/refractory Sézary syndrome. The first patient was dosed in Phase 1 study for IPH4502, their Nectin-4 ADC candidate for advanced solid tumors. Financial position remains strong with €72.5 million cash position as of March 31, 2025 (excluding €15M from Sanofi), extending runway to mid-2026. Notable developments in their ANKET® platform include ongoing trials for IPH6501 in B-NHL and strategic changes in the Sanofi partnership, including the termination of the 2016 agreement for IPH6101 and refocusing of SAR'514/IPH6401 towards autoimmune indications.

#IPHA Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Announces Q1 2025 Update: Full Executive Team to Meet Investors in NYC and Boston Key executives to present Q1 2025 progress and meet investors in New York and Boston. Join the virtual update and investor sessions. Get insights.

#IPHA Innate Pharma announces conference call and webcast for Q1 2025 business update

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting Innate Pharma presented new preclinical data for IPH4502, their novel antibody drug conjugate targeting Nectin-4, at the AACR 2025 Annual Meeting. The drug showed superior anti-tumor activity compared to enfortumab vedotin (EV) in various cancer models. Key findings include: Better performance in urothelial carcinoma models with low Nectin-4 expression Effectiveness against EV-resistant tumors Strong activity in multiple cancers including triple-negative breast cancer, head and neck, and esophageal cancers IPH4502 is currently in Phase 1 clinical trials for advanced solid tumors, with initial clinical data expected in 2026. The drug's enhanced internalization, cytotoxicity, and bystander killing effect suggest potential improved clinical benefits in areas with unmet medical needs.

#IPHA Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

www.stocktitan.net/news/IPHA/innate-pharma-...

Just loaded up on $IPHA ahead of the collab deal finalizing with $SNY $SANOFI tomorrow 🔥 Expecting that premarket surge — biotech catalysts don’t lie. LFG #stocks #biotech #premarket #IPHA #Sanofi

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company Innate Pharma SA today announce review of their January 2016 Research Collaboration and License Agreement with Sanofi:. As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development of SAR’ 514/ IPH6401 in autoimmune indications under the terms of the 2016 License Agreement; In alignment with both...

#IPHA Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma Reports Full Year 2024 Financial Results and Business Update Innate Pharma reported its 2024 financial results with several key developments. The FDA granted Breakthrough Therapy Designation to lacutamab for Sézary syndrome treatment. The company's first patient was dosed in Phase 1 study for IPH4502 (Nectin-4 ADC) in advanced solid tumors, and IPH6501 is being evaluated in B-cell non-Hodgkin's lymphoma.Financial highlights include a cash position of €91.1 million as of December 31, 2024, with runway extended to mid-2026. Revenue decreased 67.4% to €20.1 million in 2024 (from €61.6 million in 2023). The Institute for Follicular Lymphoma Innovation (IFLI) announced up to $7.9 million investment to support IPH6501 development.Notable pipeline progress includes positive data from the TELLOMAK Phase 2 study and advancement of the ANKET® platform programs. The company maintains strategic focus on NK-cell engager platform innovation and ADC program acceleration.

#IPHA Innate Pharma Reports Full Year 2024 Financial Results and Business Update

www.stocktitan.net/news/IPHA/innate-pharma-...

Breakthrough ADC Drug Tackles Treatment-Resistant Cancers: New Clinical Data Revealed New cancer drug demonstrates efficacy against treatment-resistant tumors and shows broader potential beyond urothelial carcinoma. Key data to be presented at AACR 2025.

#IPHA Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

www.stocktitan.net/news/IPHA/innate-pharma-...

Exclusive Investor Access: Innate Pharma Leadership Team Heads to Amsterdam Conference Executive team to showcase company strategy at prestigious Life Sciences Van Lanschot Kempen Conference in Amsterdam. Key updates expected. Full agenda inside.

#IPHA Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

www.stocktitan.net/news/IPHA/innate-pharma-...

Innate Pharma CEO to Lead 2024 Financial Results Discussion March 27 - Full Executive Team Joining Join Innate Pharma's leadership team for a comprehensive review of 2024 performance. CEO and CMO to present key developments in immunotherapy pipeline and financial metrics.

#IPHA Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

www.stocktitan.net/news/IPHA/innate-pharma-...

Great day at #IPHAConference2025 and hear of the IPHA
priorities inlcuding faster access to medicines, increasing clinical trials, improving Irish competitiveness and a life sciences strategy. Fantastic to connect with other industry leaders!
#SalutemInsights #Pharma #IPHA